liposomal FAK (BP-100-2.01) / Bio-Path - LARVOL DELTA

Bio-Path holdings announces clearance of Investigational New Drug application for BP1002 (GlobeNewswire) - "Bio-Path Holdings, Inc....announced that the U.S. Food and Drug Administration (FDA) has reviewed and cleared the Investigational New Drug (IND) application for BP1002 (liposomal Bcl-2), the Company’s second drug candidate. An initial Phase 1 clinical trial will evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia patients."

IND • New P1 trial